These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 14699862)

  • 1. [Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging].
    Hirohashi S; Ichikawa T; Tanimoto A; Isobe Y; Hachiya J; Saito K; Isoda H; Nishimura H; Kuwatsuru R; Gokan T; Murakami T; Nakano S; Seriu T
    Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Nov; 63(9):539-50. PubMed ID: 14699862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging.
    Shamsi K; Balzer T; Saini S; Ros PR; Nelson RC; Carter EC; Tollerfield S; Niendorf HP
    Radiology; 1998 Feb; 206(2):365-71. PubMed ID: 9457187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties.
    Kopp AF; Laniado M; Dammann F; Stern W; Grönewäller E; Balzer T; Schimpfky C; Claussen CD
    Radiology; 1997 Sep; 204(3):749-56. PubMed ID: 9280254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging.
    Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK
    Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration.
    Grandin C; Van Beers BE; Robert A; Gigot JF; Geubel A; Pringot J
    J Comput Assist Tomogr; 1995; 19(3):412-8. PubMed ID: 7790551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
    Hamm B; Staks T; Taupitz M; Maibauer R; Speidel A; Huppertz A; Frenzel T; Lawaczeck R; Wolf KJ; Lange L
    J Magn Reson Imaging; 1994; 4(5):659-68. PubMed ID: 7981510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol.
    Bluemke DA; Weber TM; Rubin D; de Lange EE; Semelka R; Redvanly RD; Chezmar J; Outwater E; Carlos R; Saini S; Holland GA; Mammone JF; Brown JJ; Milestone B; Javitt MC; Jacobs P
    Radiology; 2003 Aug; 228(2):457-64. PubMed ID: 12893904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
    Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
    AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
    J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A).
    Kehagias DT; Gouliamos AD; Smyrniotis V; Vlahos LJ
    J Magn Reson Imaging; 2001 Nov; 14(5):595-601. PubMed ID: 11747012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.
    Kim YK; Kim CS; Kwak HS; Lee JM
    J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superparamagnetic iron oxide (SPIO) enhancement in the cirrhotic liver: a comparison of two doses of ferumoxides in patients with advanced disease.
    Arnold P; Ward J; Wilson D; Ashley Guthrie J; Robinson PJ
    Magn Reson Imaging; 2003 Sep; 21(7):695-700. PubMed ID: 14559332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dynamic MR imaging of liver lesions with superparamagnetic iron oxide (SH-U-555A)].
    Saito K; Ishida J; Ito N; Kakizaki D; Kotake F; Abe K
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Feb; 61(3):84-8. PubMed ID: 11265126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted images of the liver: comparison of tumor detection before and after contrast enhancement with superparamagnetic iron oxide.
    Naganawa S; Sato C; Nakamura T; Kumada H; Ishigaki T; Miura S; Maruyama K; Takizawa O
    J Magn Reson Imaging; 2005 Jun; 21(6):836-40. PubMed ID: 15906340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence.
    Abe Y; Yamashita Y; Namimoto T; Tang Y; Takahashi M
    Radiat Med; 2000; 18(2):97-105. PubMed ID: 10888042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.
    Rappeport ED; Loft A; Berthelsen AK; von der Recke P; Larsen PN; Mogensen AM; Wettergren A; Rasmussen A; Hillingsoe J; Kirkegaard P; Thomsen C
    Acta Radiol; 2007 May; 48(4):369-78. PubMed ID: 17453514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging.
    Bellin MF; Zaim S; Auberton E; Sarfati G; Duron JJ; Khayat D; Grellet J
    Radiology; 1994 Dec; 193(3):657-63. PubMed ID: 7972804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration--preliminary clinical experience with dynamic T1-weighted MR imaging.
    Reimer P; Müller M; Marx C; Wiedermann D; Muller R; Rummeny EJ; Ebert W; Shamsi K; Peters PE
    Radiology; 1998 Dec; 209(3):831-6. PubMed ID: 9844683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
    Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
    AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.